evipedia.ai
← Back

Sodium Oligomannate for Health & Longevity

Evidence Review created on 09/25/2026 using AI4L / Opus 5.5

Also known as: GV-971, GV971, Oligomannate, Sodium Oligomannurarate, Sodium Oligo-Mannurarate, Jiuqiyi

Motivation

Sodium oligomannate (GV-971) is a mixture of short sugar chains extracted from brown seaweed and developed in China as an oral medication for Alzheimer’s disease. Unlike most brain drugs, it acts mainly in the gut, where it is thought to reshape gut bacteria and quiet the immune signals that travel from the gut to the brain. For longevity-oriented adults, it is of interest as a rare gut-based approach proposed for protecting memory and thinking.

In 2019, Chinese regulators granted it conditional approval for mild-to-moderate Alzheimer’s disease, the first new Alzheimer’s drug in that country in nearly two decades. The decision drew sharp scientific criticism, and in 2025 the license was not renewed, halting sales while a new owner continues a follow-up trial.

This review examines the human and laboratory evidence on sodium oligomannate’s effects on memory and thinking, its safety record, the competing explanations for how it might work, and what that evidence means for adults seeking to protect brain health across the lifespan.

Benefits - Risks - Protocol - Conclusion

A curated selection of expert commentary, news analysis and academic articles giving a high-level overview of sodium oligomannate.

No content on sodium oligomannate was found from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io; the drug has been marketed only in China and has not been covered on these platforms.

Grokipedia

Sodium oligomannate

An extensive AI-written encyclopedia entry covering chemistry, pharmacology, clinical development, safety and the regulatory history of the Chinese approval and its controversies.

Examine

Sodium Oligomannate

A brief entry describing sodium oligomannate as a marine-algae-derived oligosaccharide used for Alzheimer’s disease, noting that research is still ongoing, with a feed of related study summaries.

ConsumerLab

No ConsumerLab article on sodium oligomannate exists. ConsumerLab does not typically cover prescription medications, and sodium oligomannate is a prescription drug that has been approved only in China.

Systematic Reviews

Systematic reviews and meta-analyses that pool the randomized trials of sodium oligomannate, alone or alongside other Alzheimer’s drugs, for cognition and adverse events.

The claimed effect (cognition) and the principal risk (adverse events and treatment withdrawals) are both represented; no review specifically examines the raised-blood-lipid signal seen in the phase 3 trial. The phase 2 and phase 3 trials that dominate these analyses were sponsored by the manufacturer, Green Valley, which has a direct financial interest in the results.

Mechanism of Action

Sodium oligomannate is a mixture of short chains (two to ten units) of mannuronic acid, a seaweed sugar, extracted from the brown alga Ecklonia kurome. It has no single receptor target; its binding is charge-based and non-selective. Several explanations compete:

  • Gut–immune route (developer’s main hypothesis): in Alzheimer’s model mice, altered gut bacteria raise blood phenylalanine and isoleucine, driving T helper 1 (Th1) cells (inflammation-promoting white blood cells) into the brain, where they activate microglia (the brain’s resident immune cells); the drug reversed this chain (Wang et al., 2019). This work was funded and co-authored by the manufacturer, Green Valley, and co-developer Shanghai Institute of Materia Medica.
  • Direct amyloid binding: in test-tube studies it binds amyloid-beta (Aβ, the protein forming Alzheimer’s plaques) and blocks clumping (Zhou et al., 2023).
  • Gut–nerve signaling: in mice it stimulates hormone-releasing gut cells that activate the vagus nerve (the main gut-to-brain nerve) (Gong et al., 2024).
  • Counter-view: a microbiome researcher argued the developer’s own data show inflammation-linked bacteria increasing, contradicting the gut–immune route (Alzforum).

Pharmacology: oral absorption is very low (about 1% in rats, up to 9% in dogs). Absorbed drug stays in blood, reaches cerebrospinal fluid (the fluid bathing the brain) at about 5% of blood levels and is cleared mainly by the kidneys; rat intravenous half-life is under one hour (Lu et al., 2022). Human metabolism is unstudied, with no CYP (cytochrome P450, the liver’s main drug-processing enzymes) inhibition in laboratory tests; human half-life is 11–22 hours (Chinese label).

Historical Context & Evolution

Sodium oligomannate originated in research on seaweed oligosaccharides at Ocean University of China and was co-developed by the Shanghai Institute of Materia Medica and Green Valley, a Shanghai company previously criticized for marketing a lingzhi mushroom (Ganoderma lucidum) product with cancer claims (Lowe, 2019). Its original intended use was Alzheimer’s disease; early laboratory work focused on direct amyloid binding.

  • 2011–2013: a 255-person phase 2 trial missed its main cognitive goal, though more patients on 900 mg were rated stable or improved (Wang et al., 2020).
  • 2014–2018: an 818-person phase 3 trial reported a significant cognitive benefit over 36 weeks (Xiao et al., 2021). Critics noted that the placebo group improved, then declined sharply after week 24 (Alzforum). The shorter, smaller phase 2 design may explain part of the discrepancy.
  • 2019: China’s National Medical Products Administration granted conditional approval, and the mechanism was recast around gut bacteria (Wang et al., 2019).
  • 2020–2022: a 2,046-person global phase 3 trial began, then was suspended, citing COVID-19 disruption (NCT04520412).
  • 2024–2025: the license expired in November 2024 and regulators declined renewal in August 2025 (Fierce Pharma); Fosun Pharma then agreed to acquire a 53% stake to finish confirmatory trials (Fierce Pharma).

Interest for health optimization stems from its gut–brain mechanism. Independent mouse work partly reproduced the amyloid findings, in males only (Bosch et al., 2024), so the question remains open in both directions.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the only positive main cognitive result comes from a single phase 3 randomized trial, and the earlier phase 2 randomized trial missed that same endpoint.

Medium 🟩 🟩

No benefit reaches Medium: the one positive randomized trial on cognition conflicts with an earlier randomized trial and an independent network meta-analysis, so the human data are conflicting.

Low 🟩

Improved cognitive test scores in mild-to-moderate Alzheimer’s disease ⚠️ Conflicted

In an 818-person phase 3 randomized trial, 900 mg daily improved memory-and-thinking test scores over 36 weeks (Xiao et al., 2021). The phase 2 trial missed this endpoint (Wang et al., 2020); an independent network meta-analysis found no reliable benefit (Huang & Guo, 2026). Net reading: a modest, unreplicated benefit.

Magnitude: On the Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog12, a 0–75 memory and thinking test; lower is better), −2.15 points versus placebo at 36 weeks (95% confidence interval [CI, the range likely to contain the true value] −3.07 to −1.23; standardized effect size [difference in standard-deviation units] 0.53); pooled estimate across trials −1.85 points (Song et al., 2026).

Better clinician-rated overall change ⚠️ Conflicted

The Clinician’s Interview-Based Impression of Change with caregiver input (CIBIC+, a clinician’s overall rating) favored 900 mg in phase 2 but narrowly missed significance in phase 3 (Xiao et al., 2021). Daily functioning did not improve in either trial. Net reading: no reliable overall benefit is established.

Magnitude: Phase 2 stable-or-improved rate 92.8% versus 79.5% on placebo (Wang et al., 2020); phase 3 p = 0.059 (p, the probability the difference arose by chance).

Speculative 🟨

Slower decline in brain glucose use ⚠️ Conflicted

Phase 2 brain glucose-uptake scans (fluorodeoxyglucose positron emission tomography, FDG-PET) suggested slower decline, uncorrected (Wang et al., 2020). Phase 3 found none (Xiao et al., 2021). Net reading: no benefit shown on this unvalidated biomarker.

Reduced Alzheimer-type brain pathology

Mouse studies show fewer amyloid plaques, less tau (a tangle-forming nerve protein) and calmer microglia (Wang et al., 2019). Independent replication found plaque reduction only in males (Bosch et al., 2024). No human data exist.

Protection in other brain disorders

Mouse studies report less α-synuclein (Parkinson’s clumping protein) buildup (Yu et al., 2024) and less post-stroke cognitive decline via bacteria producing butyrate (an anti-inflammatory fatty acid) (Ren et al., 2025). Drug effects are animal-only.

Mood and stress resilience

In chronically stressed mice, it reduced depression- and anxiety-like behavior alongside gut-bacteria changes (He et al., 2026). Basis is animal data only; phase 3 behavior scores did not change (Xiao et al., 2021).

Metabolic and anti-inflammatory effects

Mice showed less fat, blood sugar, fatty liver (Zhang et al., 2026) and pancreas inflammation (Chen et al., 2024). Human data: one retrospective study showing lower inflammatory markers than standard drugs (Deng et al., 2026).

Benefit-Modifying Factors

  • Genetic polymorphisms: Phase 3 benefit appeared in carriers and non-carriers of APOE4 (the main inherited Alzheimer’s risk variant of a cholesterol-transport gene) (Xiao et al., 2021). No drug-processing gene variant effects are known; no CYP-mediated metabolism has been identified.
  • Baseline cognitive stage: Benefit grew as baseline Mini-Mental State Examination (MMSE, a 0–30 screening test) scores fell: 4.55 ADAS-Cog12 points at MMSE 11–14 versus 1.66 at 20–26 (Xiao et al., 2021). No data exist in normal cognition or mild cognitive impairment.
  • Baseline biomarkers: Trials diagnosed Alzheimer’s clinically, without amyloid scans or blood biomarkers, so benefit in biomarker-confirmed disease is unknown. Mouse data suggest baseline gut-bacteria composition shapes response.
  • Sex: Men and women both showed benefit in phase 3 subgroups (Xiao et al., 2021); independent mouse work found plaque reduction in males only (Bosch et al., 2024).
  • Pre-existing conditions: Trials excluded people taking cholinesterase inhibitors (drugs that raise the memory chemical acetylcholine) or memantine, and those with vascular or other dementias, so added benefit on standard therapy is unknown (Xiao et al., 2021).
  • Age: Phase 3 benefit appeared both under and over 65 (range 50–85) (Xiao et al., 2021). No data exist for cognitively healthy adults, the usual longevity-oriented user.
  • Diet and ancestry: Nearly all participants were Han Chinese; different diets and gut bacteria may change response.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: adverse-event data come from two manufacturer-sponsored randomized trials, and no individual adverse event differed from placebo consistently across both.

Medium 🟥 🟥

Raised blood lipids

In the phase 3 randomized trial, hyperlipidemia (raised blood cholesterol or triglycerides) was reported as an adverse event about twice as often with sodium oligomannate as with placebo (Xiao et al., 2021). The mechanism is unknown, and mouse studies instead suggest lipid-lowering effects. The signal comes from one manufacturer-run trial and was not described as serious.

Magnitude: 7.1% versus 3.4% of participants over 36 weeks (29 of 407 versus 14 of 410) (Xiao et al., 2021).

Low 🟥

Respiratory infections ⚠️ Conflicted

Nasopharyngitis (a cold-like nose and throat infection) was more frequent on the drug in phase 3, and one pneumonia case was judged possibly drug-related, yet upper respiratory and urinary infections were less frequent (Xiao et al., 2021). Net reading: no consistent infection risk is shown.

Magnitude: Nasopharyngitis 7.4% versus 5.6%; upper respiratory tract infection 5.7% versus 7.3% (Xiao et al., 2021).

Stopping treatment because of adverse events

Slightly more participants stopped because of adverse events on the drug in both trials (Wang et al., 2020). Neither difference was statistically significant, and total adverse-event rates were similar to or lower than placebo.

Magnitude: Phase 3: 3.4% versus 2.2% (Xiao et al., 2021); phase 2 (900 mg): 3.5% versus 1.2% (Wang et al., 2020).

Changes in bowel habits

A small 72-person Chinese trial reported increased stool frequency in the sodium oligomannate group (Zhang et al., 2022). A gut-acting, bacterially fermented oligosaccharide plausibly alters bowel habits, but the larger trials did not list digestive events among common reactions.

Magnitude: Increased stool frequency in 2 patients (reported as 5.67%) in the drug group (Zhang et al., 2022).

Autoimmune brain inflammation

The Chinese label reports autoimmune brainstem encephalitis (immune attack on the lower brain) in 2 of 577 treated trial participants, judged possibly unrelated by investigators (Chinese label). One phase 3 case was fatal; overall serious adverse events were similar to placebo (Xiao et al., 2021). The label advises vigilance.

Magnitude: 0.3% of treated participants (2 of 577) (Chinese label); serious adverse events 8.1% versus 7.1% on placebo (Xiao et al., 2021).

Heart-rhythm (QT interval) changes

The Chinese label reports transient QT-interval prolongation (a delay in the heart’s electrical recovery that can trigger dangerous rhythms) in phase 3, at similar rates on drug and placebo (Chinese label). Phase 2 heart tracings were similar between groups (Wang et al., 2020). The label advises review of heart symptoms.

Magnitude: Transient QT prolongation in 38 of 408 (9.3%) drug-treated versus 40 of 410 (9.8%) placebo participants over 36 weeks (Chinese label).

Dizziness and drowsiness

The Chinese label reports dizziness, drowsiness and muscle weakness in trials and advises routine assessment of driving and machine-operation ability (Chinese label). Phase 3 dizziness rates were similar on drug and placebo (Xiao et al., 2021). Dementia itself also impairs these abilities.

Magnitude: Dizziness in 5.7% versus 5.9% on placebo over 36 weeks (Xiao et al., 2021).

Speculative 🟨

Unfavorable shifts in gut bacteria

A microbiome researcher’s reading of the developer’s mouse data suggested increases in potentially inflammatory Desulfovibrionaceae and losses of butyrate-producing Roseburia (Alzforum). Basis is animal data interpretation only.

Risk-Modifying Factors

  • Genetic polymorphisms: No genotype-specific safety data exist. With no known CYP-mediated metabolism, drug-metabolism gene variants are unlikely to alter risk; about half of phase 3 participants carried APOE4 (Xiao et al., 2021).
  • Baseline lipids: People with already elevated LDL cholesterol (low-density lipoprotein, the main artery-clogging cholesterol) or triglycerides may be most affected by the phase 3 hyperlipidemia signal.
  • Sex: No sex-specific safety analyses are published; sex-specific gut-bacteria responses in mice suggest side effects could differ between men and women.
  • Kidney function: Absorbed drug is cleared unchanged by the kidneys (Lu et al., 2022); people with estimated glomerular filtration rate (eGFR, a kidney-filtering measure) below 60 were not specifically studied.
  • Liver and gut disease: Trials excluded inadequate liver function; inflammatory bowel disease or recent antibiotic courses may alter digestive tolerance.
  • Age: Trials enrolled ages 50–85 (mean about 70) (Xiao et al., 2021); frail very old adults and people with severe dementia were not studied.

Key Interactions & Contraindications

  • Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) and memantine: Caution. Pivotal trials excluded them, so combined safety and benefit are unstudied; possible consequences are additive side effects (slow heart rate, dizziness) or no added benefit. Heart-rate and tolerability monitoring is the usual safeguard when they are combined.
  • Antibiotics (amoxicillin, ciprofloxacin, metronidazole): Monitor. Broad-spectrum antibiotics abolished the drug’s effects in mice (Ren et al., 2025); consequence is reduced efficacy. Limiting courses to clear indications preserves the effect; no dose adjustment is established.
  • Statins (cholesterol-lowering drugs: atorvastatin, rosuvastatin): Monitor. Given the phase 3 hyperlipidemia signal, lipid control may worsen; a repeat lipid panel 8–12 weeks after starting detects this.
  • CYP-metabolized drugs (warfarin, clopidogrel, simvastatin): Low concern. The label reports no inhibition of seven CYP enzymes in laboratory tests and no human interaction studies (prescribing information); no change in these drugs’ blood levels or effects is expected, and routine monitoring applies.
  • Anti-amyloid antibodies (infused plaque-clearing antibodies: lecanemab, donanemab): Caution. No data on combined use; possible consequences are unrecognized additive adverse events or benefit that cannot be attributed to either drug. Staggered starts allow effects to be attributed.
  • Immune-modulating drugs (methotrexate, tacrolimus, adalimumab): Caution. The label warns the drug may modulate immunity and alter these agents’ efficacy (Chinese label); consequence is reduced or unpredictable immune control. Disease-activity monitoring applies when they are combined.
  • Proton pump inhibitors and laxatives (stomach-acid reducers and bowel stimulants: omeprazole, esomeprazole, bisacodyl, polyethylene glycol): Monitor. Both alter gut bacteria or transit, potentially changing response or worsening bowel changes; stable use and a bowel-habit record keep effects interpretable.
  • Probiotics and prebiotic fibers (Lactobacillus, Bifidobacterium, inulin): Monitor. Additive gut-bacteria modulation in an unpredictable direction could weaken or strengthen the drug’s effect or add bloating and bowel changes. Stable intake during treatment keeps response interpretable.
  • Supplements with additive cognitive effects (huperzine A, Ginkgo biloba): Caution. Neither was studied with the drug; huperzine A was excluded from the confirmatory trial. Possible consequences are slow heart rate (huperzine A), bleeding tendency (Ginkgo biloba) or unattributable response; heart-rate checks apply.
  • Seaweed polysaccharides (alginate, fucoidan): Monitor. Structurally related, with additive gut effects; fucoidan has mild blood-thinning activity, raising bleeding risk with anticoagulants (blood thinners: warfarin, apixaban, rivaroxaban). Clotting tests with warfarin and watching for bleeding signs apply.
  • Fecal microbiota transplantation: Caution. Replaces the gut bacteria the drug acts on, which could abolish its effect, as microbiota manipulation did in mice (Ren et al., 2025). Separate start dates keep effects attributable.

Populations who should avoid Sodium Oligomannate:

  • Known hypersensitivity to sodium oligomannate or capsule ingredients (the only label contraindication)
  • Pregnancy and breastfeeding (no human data; the drug passes into rat milk)
  • Children and adolescents under 18 years (no data)
  • Severe dementia (MMSE below 11), not studied
  • Resting heart rate below 50 beats per minute (excluded from the confirmatory trial, NCT05908695)
  • Severe kidney impairment (eGFR below 30 mL/min/1.73 m²) or moderate-to-severe liver impairment (Child-Pugh Class B or C, a liver-disease severity score), not studied
  • Cognitively healthy adults seeking prevention, for whom no efficacy or safety data exist

Risk Mitigation Strategies

  • Diagnostic confirmation first: Confirmation of Alzheimer’s pathology by amyloid scan or blood phosphorylated tau 217 (p-tau217) before use, preventing exposure to side effects without the only documented benefit.
  • Lipid monitoring: Fasting lipid panel at baseline, 12 weeks, then every 6 months to catch the hyperlipidemia signal; an LDL cholesterol rise above 15% is the usual trigger for dietary or lipid-therapy adjustment.
  • Kidney and liver checks: eGFR and alanine aminotransferase (ALT, a liver enzyme) at baseline and 3 months, limiting accumulation risk where clearance is impaired.
  • Symptom log: A record of stool frequency, respiratory infections, dizziness and new neurological symptoms during the first 12 weeks, identifying bowel changes, infection or encephalitis signals early.
  • Antibiotic stewardship: Antibiotic use limited to clear indications, preventing loss of the gut-mediated effect.
  • Verified supply only: Product sourced only through licensed channels, avoiding counterfeit or contaminated capsules while legitimate supply is suspended.
  • Scheduled cognitive testing: Montreal Cognitive Assessment (MoCA, a 30-point screen) every 6 months; accelerating decline is the usual stopping point, avoiding prolonged use of an ineffective drug.

Therapeutic Protocol

  • Standard regimen: 450 mg (three 150 mg capsules) orally twice daily, 900 mg per day, per the Chinese label and phase 3 trial (Xiao et al., 2021); developed and promoted by Green Valley and Meiyu Geng’s team.
  • Dose-finding: 600 mg per day was tested in phase 2 and performed no better than placebo; no lower maintenance dose is validated (Wang et al., 2020).
  • Time of day: Morning and evening doses; the label permits intake fasting or with food, and no evidence favors a particular time.
  • Half-life: About 11–22 hours in people per the Chinese label, consistent with twice-daily use; in rats it is under one hour after intravenous dosing and 3–8 hours after oral dosing (Lu et al., 2022).
  • Single versus split dose: All trials split the dose twice daily; once-daily dosing is untested.
  • Alternative approaches: Cholinesterase inhibitors (donepezil) or memantine, standard in Western neurology; anti-amyloid infusions (lecanemab, from Eisai and Biogen) for early disease; multidomain lifestyle programs (the FINGER model, Miia Kivipelto).
  • Genetic polymorphisms: No dose adjustment for APOE4 or drug-metabolism variants.
  • Sex: Same dose for men and women; mouse data hint at stronger male responses.
  • Age: Same dose across the studied 50–85 age range; no data beyond 85.
  • Baseline biomarkers: Lower baseline MMSE predicted a larger effect (Xiao et al., 2021); no biomarker-guided dosing exists.
  • Pre-existing conditions: No dose rules exist for kidney or liver impairment, which were not studied.
  • Duration: Efficacy was tested for 36 weeks; longer-term efficacy is under study.

Discontinuation & Cycling

  • Intended duration: Used as ongoing symptom therapy while benefit persists; controlled data extend only to 36 weeks.
  • Withdrawal effects: None reported; trials did not include a withdrawal phase, so post-stopping cognitive decline is uncharacterized.
  • Tapering: No taper is described; trials stopped the drug abruptly at study end without reported problems.
  • Cycling: No evidence supports cycling; gut-bacteria changes may revert after stopping, which argues against intermittent use.
  • Stopping triggers: Typical stopping points are lack of stabilization after 6 months, intolerable side effects, or loss of legitimate supply, as occurred in China in 2025.

Sourcing and Quality

  • Single manufacturer: Only Green Valley (Shanghai) Pharmaceuticals produced it under Chinese approval number H20190031; production stopped in 2025 after the license lapsed (Fierce Pharma).
  • Formulation: 150 mg capsules, 42 per box; a mixture of mannuronic acid chains whose consistency depends on a proprietary seaweed-extraction process.
  • Not a supplement equivalent: Alginate oligosaccharides or seaweed extracts sold as supplements differ in composition and are untested for this use; no third-party testing (United States Pharmacopeia, ConsumerLab) exists for either.
  • Counterfeit risk: Experts warned that restricted access invites counterfeits (Alzforum); product from unofficial channels cannot be verified.
  • Compounding pharmacies: Not applicable; no compounding pharmacy prepares this multi-component drug.
  • Storage: Sealed, below 25°C; labeled shelf life 24 months.

Practical Considerations

  • Time to effect: In phase 3, cognitive-score separation appeared by week 4 and was judged at 36 weeks (Xiao et al., 2021).
  • Common pitfalls: Assuming benefit in healthy aging; stopping standard Alzheimer’s drugs to switch; expecting slowed disease progression, which is unproven; buying unverified product.
  • Regulatory status: Conditionally approved in China in 2019; license expired November 2024 and renewal was declined August 2025; never approved by the US Food and Drug Administration or European Medicines Agency.
  • Cost and accessibility: About 296 yuan (roughly $41) per box, four boxes per month, while marketed; currently not legally sold anywhere, which makes access exceptionally difficult.
  • Payer incentives: Chinese national insurance reimbursed it from 2022 at a price far below infusion antibodies; payers have a structural incentive to favor cheap oral drugs, a potential bias in listing and funding decisions.
  • Conflict of interest: Nearly all human and mechanistic data come from the manufacturer and its co-developer, which have a direct financial stake in adoption.

Interaction with Foundational Habits

  • Sleep: None known; no trial measured sleep. A theoretical indirect link exists through gut-to-vagus-nerve serotonin signaling seen in mice (Gong et al., 2024). Practical consideration: sleep-quality tracking over the first 12 weeks detects changes.
  • Nutrition: Indirect, potentially potentiating: the drug acts through gut bacteria, so fiber-rich, Mediterranean-style eating (25–35 g fiber daily) plausibly shapes response. Saturated-fat intake bears directly on the phase 3 lipid signal. The label permits intake with or without food.
  • Exercise: None known; no blunting reported. Aerobic exercise independently supports cognition and gut-bacteria diversity, so the two can be combined without timing constraints.
  • Stress management: Indirect: in mice it reduced depression-like behavior under chronic stress with gut–brain changes (He et al., 2026), but behavioral and mood scores did not change in the phase 3 trial (Xiao et al., 2021).

Monitoring Protocol & Defining Success

Baseline testing before starting establishes the diagnosis and safety reference points: biomarker confirmation of Alzheimer’s pathology, a fasting lipid panel, blood sugar, kidney and liver function, an inflammation marker, resting heart rate and a structured cognitive score recorded with a caregiver present. Because nearly all evidence concerns diagnosed mild-to-moderate disease, success is defined as stable or improved cognitive scores and daily functioning rather than any biomarker shift.

Ongoing monitoring follows a set cadence: labs at 12 weeks, 24 weeks, then every 6 months; cognitive testing at 12 weeks and every 6 months. A lipid rise, new kidney or liver changes, or accelerating cognitive decline at any visit prompts review of continued use. Consistent time of day and laboratory across visits keep results comparable.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
LDL cholesterol <100 mg/dL Phase 3 lipid signal Conventional <130 mg/dL; fasting 9–12 hours; pair with triglycerides and ApoB (apolipoprotein B, a count of artery-clogging particles)
Triglycerides <100 mg/dL Phase 3 lipid signal Conventional <150 mg/dL; fasting sample; recent alcohol raises values
Fasting glucose / HbA1c 75–90 mg/dL / <5.4% Metabolic baseline HbA1c = glycated hemoglobin, average blood sugar over about 3 months; conventional <100 mg/dL / <5.7%
eGFR >90 mL/min/1.73 m² Renal clearance of drug Conventional >60; pair with cystatin C (a muscle-independent kidney marker)
ALT <25 U/L Liver safety Conventional upper limit about 40–55 U/L; pair with AST (aspartate aminotransferase, another liver enzyme)
hs-CRP <1.0 mg/L Systemic inflammation hs-CRP = high-sensitivity C-reactive protein; conventional <3.0 mg/L; not validated as a drug-response marker; values unreliable during infection
Plasma p-tau217 No established functional target; interpret against the assay’s validated cut-off Confirms Alzheimer’s pathology Baseline only; amyloid scan is the alternative confirmation
MoCA No established target in diagnosed disease; track change from own baseline Tracks cognitive response ≥26 is normal in healthy adults; alternate test versions limit practice effects; same time of day at each test

Qualitative markers of success:

  • Memory for recent events and appointments
  • Word-finding and conversational ease
  • Independence in daily tasks, rated by a caregiver
  • Mood, agitation and sleep quality
  • Bowel habits and digestive comfort
  • Energy and engagement in usual activities

Emerging Research

  • Confirmatory phase 4 trial (China): 36-week randomized placebo-controlled trial, 1,312 planned participants with mild-to-moderate Alzheimer’s disease; primary endpoints ADAS-Cog12 and daily-living scores, with spinal-fluid and immune biomarkers (NCT05908695). Results due around 2029 could restore or end the case.
  • Global phase 3 trial: 2,046 planned participants in the US, Europe and China, suspended citing COVID-19 disruption (NCT04520412); the new owner has stated intent to resume international studies (Fierce Pharma).
  • Long-term safety and efficacy studies: A 2,500-person phase 4 safety study (NCT05058040) and an 800-person efficacy study with blood and gut-bacteria biomarkers (NCT05181475), both active but not recruiting.
  • Post-stroke cognitive impairment: A 116-person study in acute ischemic stroke (stroke caused by a blocked artery) (NCT05545605) builds on mouse and human butyrate findings from Ren et al., 2025.
  • Evidence that could weaken the case: An independent network meta-analysis found no newer drug, sodium oligomannate included, reliably beat placebo (Huang & Guo, 2026); independent mouse replication showed male-only effects (Bosch et al., 2024).
  • New indications in animals: Mouse work on obesity via bile-acid signaling (Zhang et al., 2026) and Parkinson’s-type protein clumping (Yu et al., 2024) could widen relevance to healthy aging if confirmed in people.

Conclusion

Sodium oligomannate is a seaweed-derived sugar mixture that acts mainly in the gut and was sold in China for several years as a treatment for mild-to-moderate Alzheimer’s disease. Its human evidence rests on one large positive trial showing better scores on a memory and thinking test, set against an earlier trial that missed its main goal, no clear gain in daily functioning, and an unusual pattern in the comparison group that critics have questioned.

Nearly all human evidence, and much of the laboratory work, comes from the manufacturer and its research partner, which have a direct financial interest in the drug’s success. Independent animal work has partly reproduced the brain findings, but only in males. Reports of lower body weight, blood sugar and inflammation come mainly from animal studies.

Side effects in trials were broadly similar to those with a placebo, apart from a signal for raised blood fats. The gut-bacteria explanation is plausible but disputed.

For longevity-oriented adults without diagnosed Alzheimer’s disease, no human data on prevention or healthy brain aging exist, so any benefit in that setting is unknown. The license lapsed in 2025 and the drug is not approved elsewhere, so legitimate supply is currently unavailable. The overall picture is a modest, unconfirmed effect on symptoms in diagnosed disease, a reassuring but short safety record, and an open scientific question.

Top - Benefits - Risks - Protocol